Answers are grounded in this paper and cite their sources.
Congenital acute myeloid leukemia (C-AML) is a rare and aggressive hematologic malignancy diagnosed within the first month of life. It represents significant diagnostic and therapeutic challenges due to its nonspecific clinical presentation and the limited tolerance of neonates to intensive chemotherapy. Trisomy 21 is the most frequently associated chromosomal abnormality, and GATA1 mutations play a key role in leukemogenesis in this context. We report a retrospective, descriptive series of three male neonates diagnosed with C-AML at a single tertiary care center between 2011 and 2026. All three presented with dysmorphic facial features suggestive of trisomy 21, respiratory distress, and cutaneous or systemic involvement, with varying degrees of cytopenia and marked hyperleukocytosis. Immunophenotyping confirmed acute megakaryoblastic leukemia (AML M7) in two infants, both with aberrant CD7 expression, and AML M2 in the third. All three also had congenital heart defects. Management included supportive care, and chemotherapy where feasible. All patients died during the neonatal period. These cases illustrate the aggressive course and diagnostic complexity of C-AML. Early clinical suspicion, particularly in neonates with syndromic features such as Down syndrome, is essential. Prompt immunophenotypic confirmation, cardiac assessment before any chemotherapy, individualized supportive care, and multidisciplinary neonatal–hematologic management are critical to improving outcomes.
No takes yet. Share an insight, caveat, or question.
Sejjali et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: